{"preliminary_commentary":{"by_channel":{"youtube":1,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"HOVON150AML","nct_id":"NCT03839771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hovon150aml-nct03839771. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HOVON150AML","arms":[{"description":"Cycle 1: day 1-start cycle 2 \\| Cycle 2: day 1 - start consolidation treatment \\| Consolidation treatment: day 1 - start maintenance \\| Maintenance treatment: day 1- day 730 (2 years) \\|\n\nThe dosage for Placebo for AG-120 (IDH1): 500 mg dose/day\n\nThe dosage for Placebo for AG-221 (IDH2): 100mg dose/day","label":"Arm A: Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Cycle 1: day 1-start cycle 2 \\| Cycle 2: day 1 - start consolidation treatment \\| Consolidation treatment: day 1 - start maintenance \\| Maintenance treatment: day 1- day 730 (2 years) \\|\n\nThe dosage for AG-120 (IDH1): 500 mg dose/day\n\nThe dosage for AG-221 (IDH2): 100mg dose/day","label":"Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)","type":"EXPERIMENTAL"}],"collaborators":["University of Ulm"],"completion_date":{"date":"2034-09-19","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome With Excess Blasts-2"],"enrollment":{"count":968,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AG-120","otherNames":["Ivosidenib"],"type":"DRUG"},{"name":"Placebo for AG-120","otherNames":[],"type":"DRUG"},{"name":"AG-221","otherNames":["Enasidenib"],"type":"DRUG"},{"name":"Placebo for AG-221","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","official_title":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04-17","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival (EFS)","timeFrame":"Approximately up to 60 months following first patient enrollment"}],"references":[],"start_date":{"date":"2019-03-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03839771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hovon150aml-nct03839771"}